Andy Reddick has resumed full responsibilities as president and CEO of Acura Pharmaceuticals following his medical leave of absence initiated in February of this year.
Patrik De Haes, MD, currently COO, has been appointed to succeed Professor Desire Collen as ThromboGenics' new CEO.
Zealand Pharma announced that Dr. David H Solomon has been appointed CEO.
Micromet has named Barclay A. Phillips as senior vice president and CFO.
Wayne D. Comper, Ph.D., D.Sc., has joined Exosome Diagnostics as the chief scientific officer. Tom Tsakeris has been appointed director of regulatory affairs.
Halozyme Therapeutics has named Patrick O'Connor, PhD, vice president, research, Michael J. LaBarre, PhD, vice president, product development, and James E. Cartoni, vice president, legal.
MDS Pharma Services, has hired Ross Tonkens, MD, to provide medical oversight for its Phase IIa clinical research activities and to direct the medical and clinical activities of its Development & Regulatory Services line of business.
Cadence Pharamaceuticals has named Todd Rich, M.D. to the company's board of directors and Malcolm Lloyd-Smith to the position of senior vice president, regulatory affairs and quality assurance.
Axial Biotech has named Rina Wolf as the company's new vice president of reimbursement and regulatory affairs.
National Cancer Institute has named Dr. Marybeth S. Hughes, MD as the principal investigator for the current Phase III and Phase II clinical trials of Delcath Systems' Percutaneous Hepatic Perfusion System.
Asterand has named Jonathan J. Fleming as a non-executive director.
Synergy Pharmaceuticals. appointed Melvin K. Spigelman, M.D. as a director of the company.
Metabolic Research has named Bradford van Siclen to its board of directors.
Aryx Therapeutics has named David Beier to its board of directors.
FibroGen has appointed Toshinari Tamura to its board of directors
Patricia Trottier, a member of the board of directors of CV Technologies since 2004, has decided to resign from the board for personal reasons.
Brainstorm Cell Therapeutics has named Dr. Robert H. Brown Jr, MD, PhD, to the company's scientific advisory board.